Sharekhan
Volume growth sustains; Low input cost and efficiencies led to margin expansion: GSK Consumer reported strong results in Q4FY2019, with broad-based growth across products and channels. Revenue grew by 9%, driven by 6.3% volume growth. Business auxiliary income rose by 20% y-o-y, led by double-digit growth across all products. Unlike other FMCG companies, GSK...
GlaxoSmithKline Pharmaceuticals Ltd. is trading below its 30 day SMA of 3214.2
More from GlaxoSmithKline Pharmaceuticals Ltd.
Recommended